This page collects WhisperX intelligence signals tagged #drug launch. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
Celcuity has laid out a bold commercial forecast, projecting its lead drug candidate, gedatolisib, could achieve up to $2.5 billion in annual peak revenue. This significant financial target is tied directly to the successful execution of the company's ongoing pivotal clinical trials and its parallel preparations for a ...
Celldex Therapeutics has moved to secure a significant war chest, pricing a $300 million public offering of its common stock at $29 per share. This capital raise is a direct and substantial bet on the commercial future of its lead candidate, barzolvolimab. The move signals the company's transition from a clinical-stage...